Adam Crystal Sells 27,000 Shares of Tango Therapeutics (NASDAQ:TNGX) Stock

Tango Therapeutics, Inc. (NASDAQ:TNGX) insider Adam Crystal sold 27,000 shares of Tango Therapeutics stock in a transaction on Monday, June 1st. The stock was sold at an average price of $22.87, for a total value of $617,490.00. Following the sale, the insider owned 115,743 shares in the company, valued at $2,647,042.41. This trade represents a 18.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link.

Adam Crystal also recently made the following trade(s):

• On Friday, May 1st, Adam Crystal sold 27,000 shares of Tango Therapeutics stock. The shares were sold at an average price of $21.23, for a total value of $573,210.00.
• On Wednesday, April 15th, Adam Crystal sold 38,460 shares of Tango Therapeutics stock. The stock was sold at an average price of $25.00, for a total value of $961,500.00.
• On Wednesday, April 1st, Adam Crystal sold 27,000 shares of Tango Therapeutics stock. The stock was sold at an average price of $21.20, for a total transaction of $572,400.00.
• On Wednesday, March 25th, Adam Crystal sold 12,000 shares of Tango Therapeutics stock. The shares were sold at an average price of $20.11, for a total transaction of $241,320.00.
• On Thursday, March 5th, Adam Crystal sold 20,251 shares of Tango Therapeutics stock. The stock was sold at an average price of $15.00, for a total transaction of $303,765.00.

Tango Therapeutics Stock Performance

Shares of TNGX stock opened at $22.15 on Friday. The firm has a market cap of $3.20 billion, a price-to-earnings ratio of -26.69 and a beta of 1.19. Tango Therapeutics, Inc. has a 52 week low of $3.12 and a 52 week high of $28.41. The firm’s 50-day simple moving average is $22.44 and its two-hundred day simple moving average is $15.58.

Tango Therapeutics (NASDAQ:TNGX) last released its earnings results on Wednesday, May 13th. The company reported ($0.32) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.32). Tango Therapeutics had a negative net margin of 151.15% and a negative return on equity of 41.54%. Analysts forecast that Tango Therapeutics, Inc. will post -1.33 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. Stifel Nicolaus raised their target price on Tango Therapeutics from $24.00 to $40.00 and gave the stock a “buy” rating in a research report on Monday, April 27th. Mizuho increased their price target on Tango Therapeutics from $20.00 to $30.00 and gave the stock an “outperform” rating in a research note on Friday, May 15th. B. Riley Financial reissued a “buy” rating on shares of Tango Therapeutics in a report on Friday, March 27th. Jefferies Financial Group lowered Tango Therapeutics from a “buy” rating to a “hold” rating and lifted their price objective for the stock from $18.00 to $27.00 in a report on Thursday, May 14th. Finally, Weiss Ratings downgraded shares of Tango Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, May 28th. Ten equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $32.27.

Institutional Investors Weigh In On Tango Therapeutics

Institutional investors have recently made changes to their positions in the stock. Global Retirement Partners LLC purchased a new position in shares of Tango Therapeutics in the fourth quarter valued at $35,000. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Tango Therapeutics by 148,800.0% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,467 shares of the company’s stock valued at $40,000 after purchasing an additional 4,464 shares during the period. ANTIPODES PARTNERS Ltd purchased a new stake in Tango Therapeutics during the 4th quarter worth about $40,000. State of Wyoming bought a new position in Tango Therapeutics in the 1st quarter worth about $128,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its holdings in Tango Therapeutics by 52.2% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,544 shares of the company’s stock valued at $58,000 after buying an additional 2,243 shares in the last quarter. Hedge funds and other institutional investors own 78.99% of the company’s stock.

About Tango Therapeutics

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.